BR112019019553A2 - inibidores - Google Patents
inibidores Download PDFInfo
- Publication number
- BR112019019553A2 BR112019019553A2 BR112019019553-0A BR112019019553A BR112019019553A2 BR 112019019553 A2 BR112019019553 A2 BR 112019019553A2 BR 112019019553 A BR112019019553 A BR 112019019553A BR 112019019553 A2 BR112019019553 A2 BR 112019019553A2
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- compound
- phenyl
- formula
- benzodiazol
- Prior art date
Links
- 0 C*(C)C1=CC2NC=NC2C=C1 Chemical compound C*(C)C1=CC2NC=NC2C=C1 0.000 description 15
- FCQTZASBYBRYGM-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1c1cnc(N)[s]1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1c1cnc(N)[s]1)=O FCQTZASBYBRYGM-UHFFFAOYSA-N 0.000 description 1
- ZVZZUQQFIRPPBU-UHFFFAOYSA-N CC(C)(C)OC([n]1c(ccc(C)c2)c2nc1)=O Chemical compound CC(C)(C)OC([n]1c(ccc(C)c2)c2nc1)=O ZVZZUQQFIRPPBU-UHFFFAOYSA-N 0.000 description 1
- YPVUVTIITAMAPQ-UHFFFAOYSA-N CC(C)(C)c1cnc(N)[s]1 Chemical compound CC(C)(C)c1cnc(N)[s]1 YPVUVTIITAMAPQ-UHFFFAOYSA-N 0.000 description 1
- CAGCXAKEJGNJRJ-UHFFFAOYSA-N CC(C)(C)c1nnc[n]1C Chemical compound CC(C)(C)c1nnc[n]1C CAGCXAKEJGNJRJ-UHFFFAOYSA-N 0.000 description 1
- QGJNOZWTBQSBED-UHFFFAOYSA-N CC(CCCc1nnc(N)[s]1)c(cccc1)c1-c(cc1)ccc1F Chemical compound CC(CCCc1nnc(N)[s]1)c(cccc1)c1-c(cc1)ccc1F QGJNOZWTBQSBED-UHFFFAOYSA-N 0.000 description 1
- UOGYMJMDRUCIAE-UHFFFAOYSA-N CC(Nc1nnc(CCCN=S(C)(c2ccc(C)cc2)=O)[s]1)=O Chemical compound CC(Nc1nnc(CCCN=S(C)(c2ccc(C)cc2)=O)[s]1)=O UOGYMJMDRUCIAE-UHFFFAOYSA-N 0.000 description 1
- RUFHDCVELMTFEB-UHFFFAOYSA-N CC(Nc1nnc(CCCNS(c2ccc(C)cc2)(=O)=O)[s]1)=O Chemical compound CC(Nc1nnc(CCCNS(c2ccc(C)cc2)(=O)=O)[s]1)=O RUFHDCVELMTFEB-UHFFFAOYSA-N 0.000 description 1
- ORIWBDUUQYFUBC-UHFFFAOYSA-N CCC(C)(C)c1nnc(N)[s]1 Chemical compound CCC(C)(C)c1nnc(N)[s]1 ORIWBDUUQYFUBC-UHFFFAOYSA-N 0.000 description 1
- BWZAUUOMQWNIAQ-UHFFFAOYSA-N CNC(c(cc1)ccc1Cl)=N Chemical compound CNC(c(cc1)ccc1Cl)=N BWZAUUOMQWNIAQ-UHFFFAOYSA-N 0.000 description 1
- UHVBQPJDHCBRCZ-UHFFFAOYSA-N CNC1C=CC=CC1c(cc1)ccc1F Chemical compound CNC1C=CC=CC1c(cc1)ccc1F UHVBQPJDHCBRCZ-UHFFFAOYSA-N 0.000 description 1
- MKVFBQSTWGWZKG-UHFFFAOYSA-N COc(c(OC)c1)ccc1NS(NCCCl)(=O)=O Chemical compound COc(c(OC)c1)ccc1NS(NCCCl)(=O)=O MKVFBQSTWGWZKG-UHFFFAOYSA-N 0.000 description 1
- RDEXBSOAXBVEAK-UHFFFAOYSA-N C[n]1c(SCCNS(Nc(cc2)cc(OC)c2OC)(=O)=O)nnc1 Chemical compound C[n]1c(SCCNS(Nc(cc2)cc(OC)c2OC)(=O)=O)nnc1 RDEXBSOAXBVEAK-UHFFFAOYSA-N 0.000 description 1
- MVXBTNKLCLGJLM-UHFFFAOYSA-N Cc(cc1)ccc1-c1c(Nc(cc2)ccc2-c2nnc(N)[s]2)nccc1 Chemical compound Cc(cc1)ccc1-c1c(Nc(cc2)ccc2-c2nnc(N)[s]2)nccc1 MVXBTNKLCLGJLM-UHFFFAOYSA-N 0.000 description 1
- GXWAEKRPYMYEBK-UHFFFAOYSA-N Cc(cc1)ccc1S(C)(=NCCCc1nnc(N)[s]1)=O Chemical compound Cc(cc1)ccc1S(C)(=NCCCc1nnc(N)[s]1)=O GXWAEKRPYMYEBK-UHFFFAOYSA-N 0.000 description 1
- IIAIIDAZJMDYJK-UHFFFAOYSA-N Cc(cc1)ccc1S(N(CC1)CCC1c1cnc(N)[s]1)(=O)=O Chemical compound Cc(cc1)ccc1S(N(CC1)CCC1c1cnc(N)[s]1)(=O)=O IIAIIDAZJMDYJK-UHFFFAOYSA-N 0.000 description 1
- YKEZOKIPIIBNDN-UHFFFAOYSA-N O=S(NCCCl)(Cl)=O Chemical compound O=S(NCCCl)(Cl)=O YKEZOKIPIIBNDN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1705263.0 | 2017-03-31 | ||
| GBGB1705263.0A GB201705263D0 (en) | 2017-03-31 | 2017-03-31 | Novel inhibitors |
| PCT/EP2018/058391 WO2018178384A1 (en) | 2017-03-31 | 2018-04-03 | Novel inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019019553A2 true BR112019019553A2 (pt) | 2020-04-22 |
Family
ID=58682483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019019553-0A BR112019019553A2 (pt) | 2017-03-31 | 2018-04-03 | inibidores |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11339152B2 (enExample) |
| EP (1) | EP3601269A1 (enExample) |
| JP (3) | JP7674811B2 (enExample) |
| KR (2) | KR20250002689A (enExample) |
| CN (2) | CN110719910B (enExample) |
| AU (2) | AU2018246382C1 (enExample) |
| BR (1) | BR112019019553A2 (enExample) |
| CA (2) | CA3057783A1 (enExample) |
| EA (1) | EA201992120A1 (enExample) |
| GB (1) | GB201705263D0 (enExample) |
| IL (3) | IL297534A (enExample) |
| MX (2) | MX2019011544A (enExample) |
| NZ (2) | NZ792694A (enExample) |
| WO (1) | WO2018178384A1 (enExample) |
| ZA (1) | ZA201905811B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2536650A (en) | 2015-03-24 | 2016-09-28 | Augmedics Ltd | Method and system for combining video-based and optic-based augmented reality in a near eye display |
| US12458411B2 (en) | 2017-12-07 | 2025-11-04 | Augmedics Ltd. | Spinous process clamp |
| EP3787543A4 (en) | 2018-05-02 | 2022-01-19 | Augmedics Ltd. | REGISTRATION OF A FIDUCIAL MARKER FOR AN AUGMENTED REALITY SYSTEM |
| EP3861001B1 (en) * | 2018-10-05 | 2023-12-13 | Pfizer Inc. | Boron containing pde4 inhibitors |
| US11766296B2 (en) | 2018-11-26 | 2023-09-26 | Augmedics Ltd. | Tracking system for image-guided surgery |
| CN113365978A (zh) * | 2019-01-06 | 2021-09-07 | 普梭梅根公司 | Htra抑制剂和caga抑制剂及其应用 |
| US11980506B2 (en) | 2019-07-29 | 2024-05-14 | Augmedics Ltd. | Fiducial marker |
| US12178666B2 (en) | 2019-07-29 | 2024-12-31 | Augmedics Ltd. | Fiducial marker |
| US11382712B2 (en) | 2019-12-22 | 2022-07-12 | Augmedics Ltd. | Mirroring in image guided surgery |
| EP4065553B1 (en) * | 2020-01-17 | 2025-01-29 | Daegu-Gyeongbuk Medical Innovation Foundation | Novel compound, preparation method thereof, and use thereof |
| KR102433502B1 (ko) * | 2020-01-17 | 2022-08-18 | 재단법인 대구경북첨단의료산업진흥재단 | 신규 화합물, 이의 제조방법 및 이의 용도 |
| US11389252B2 (en) | 2020-06-15 | 2022-07-19 | Augmedics Ltd. | Rotating marker for image guided surgery |
| US12239385B2 (en) | 2020-09-09 | 2025-03-04 | Augmedics Ltd. | Universal tool adapter |
| US20230382891A1 (en) * | 2020-10-20 | 2023-11-30 | Blacksmith Medicines, Inc. | Glutaminyl-peptide cyclotransferase like (qpctl) protein inhibitors and uses thereof |
| LT4259617T (lt) * | 2020-12-10 | 2024-12-10 | Bayer Aktiengesellschaft | Pakeistos pirazolo piperidino karboksirūgštys |
| US11896445B2 (en) | 2021-07-07 | 2024-02-13 | Augmedics Ltd. | Iliac pin and adapter |
| US12150821B2 (en) | 2021-07-29 | 2024-11-26 | Augmedics Ltd. | Rotating marker and adapter for image-guided surgery |
| EP4387552A4 (en) | 2021-08-18 | 2025-04-30 | Augmedics Ltd. | AUGMENTED REALITY SURGICAL SYSTEM USING DEPTH SENSING |
| CN117567435A (zh) * | 2022-01-30 | 2024-02-20 | 上海市第十人民医院 | 谷氨酰胺环化酶抑制剂及其应用 |
| WO2023205173A1 (en) * | 2022-04-20 | 2023-10-26 | Blacksmith Medicines, Inc. | Substituted piperidines and substituted tetrahydropyridines as immune-modulating compounds |
| WO2023203521A1 (en) | 2022-04-21 | 2023-10-26 | Augmedics Ltd. | Systems and methods for medical image visualization |
| CN114560817B (zh) * | 2022-04-25 | 2022-10-25 | 北京大学第三医院（北京大学第三临床医学院） | 一种用于抑制纤维化的小分子药物及其应用 |
| AR130003A1 (es) | 2022-08-03 | 2024-10-23 | Boehringer Ingelheim Int | Derivados de piperidinilpiridinilcarbonitrilo como inhibidores de glutaminil-péptido ciclotransferasa y proteína tipo glutaminil-péptido ciclotransferasa |
| IL319523A (en) | 2022-09-13 | 2025-05-01 | Augmedics Ltd | Augmented reality glasses for image-guided medical intervention |
| WO2024131742A1 (zh) * | 2022-12-20 | 2024-06-27 | 深圳湾实验室 | 一种靶向usp1的小分子抑制剂及其应用 |
| AU2023411110A1 (en) | 2022-12-22 | 2025-04-24 | Boehringer Ingelheim International Gmbh | Phenylpiperidine derivatives as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase like protein |
| AU2024236795A1 (en) | 2023-03-13 | 2025-06-26 | Boehringer Ingelheim International Gmbh | Phenylpiperidine derivatives as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase like protein |
| US20250059165A1 (en) | 2023-08-04 | 2025-02-20 | Boehringer Ingelheim International Gmbh | Piperidinylpyridinylcarbonitrile derivatives as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase like protein |
| TW202521532A (zh) | 2023-08-04 | 2025-06-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為麩醯胺醯基肽環轉移酶及麩醯胺醯基肽環轉移酶樣蛋白之抑制劑的哌啶基吡啶基甲腈衍生物 |
| US20250066329A1 (en) | 2023-08-14 | 2025-02-27 | Boehringer Ingelheim International Gmbh | Piperidinylpyridinylcarbonitrile derivatives as inhibitors of glutaminyl-peptide cyclotransferase and glutaminyl-peptide cyclotransferase like protein |
| CN117538462B (zh) * | 2024-01-10 | 2024-03-26 | 地奥集团成都药业股份有限公司 | 一种氨氯地平贝那普利胶囊有关物质的检测方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2114662T3 (es) * | 1993-08-26 | 1998-06-01 | Ono Pharmaceutical Co | Derivados de la 4-aminopirimidina. |
| US6262059B1 (en) * | 1995-06-07 | 2001-07-17 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with quinazoline derivatives |
| US7642278B2 (en) * | 2001-07-03 | 2010-01-05 | Novartis Vaccines And Diagnostics, Inc. | Indazole benzimidazole compounds |
| WO2003004488A1 (en) * | 2001-07-03 | 2003-01-16 | Chiron Corporation | Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| US8673924B2 (en) * | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| US20090048301A1 (en) * | 2003-07-09 | 2009-02-19 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
| EA011300B1 (ru) * | 2003-07-16 | 2009-02-27 | Янссен Фармацевтика Н.В. | Производные триазолопиримидина в качестве ингибиторов киназы гликогенсинтазы-3 |
| ES2287896T3 (es) * | 2004-01-12 | 2007-12-16 | Laboratoires Serono Sa | Derivados de tiazol y uso de los mismos. |
| RU2377988C2 (ru) * | 2004-02-20 | 2010-01-10 | Новартис Вэксинес Энд Дайэгностикс, Инк. | Модуляция воспалительных и метастатических процессов |
| BRPI0513405A (pt) * | 2004-07-16 | 2008-05-06 | Sunesis Pharmaceuticals Inc | tienopirimidinas úteis como inibidores de aurora quinase |
| MX2007001399A (es) * | 2004-08-02 | 2007-04-18 | Osi Pharm Inc | Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas. |
| GB0520958D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
| JP2009531274A (ja) * | 2005-12-07 | 2009-09-03 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | キナーゼ阻害性ピロロピリジン化合物 |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| TW200808739A (en) * | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
| US7893058B2 (en) * | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| AU2007272972B2 (en) * | 2006-07-14 | 2011-12-01 | Chemocentryx, Inc. | Triazolyl pyridyl benzenesulfonamides as CCR2 or CCR9 modulators for the treatment of atherosclerosis |
| CA2673003A1 (en) * | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines for pdk1 inhibition |
| BRPI0720635A2 (pt) * | 2006-12-22 | 2014-01-07 | Novartis Ag | Compostos orgânicos e seus usos |
| EP2200436B1 (en) * | 2007-09-04 | 2015-01-21 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
| AU2009282567B2 (en) * | 2008-08-20 | 2014-10-02 | Merck Sharp & Dohme Corp. | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| JP5707327B2 (ja) * | 2008-09-04 | 2015-04-30 | プロビオドルグ エージー | 新規の阻害剤 |
| EP2475428B1 (en) * | 2009-09-11 | 2015-07-01 | Probiodrug AG | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| BR112012022478B1 (pt) * | 2010-03-10 | 2021-09-21 | Probiodrug Ag | Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica |
| JP5945532B2 (ja) * | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
| EP2638018A1 (en) * | 2010-11-09 | 2013-09-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
| ES2746134T3 (es) * | 2010-11-10 | 2020-03-04 | Genentech Inc | Derivados de pirazol aminopirimidina como moduladores de LRRK2 |
| US8785459B2 (en) * | 2011-12-27 | 2014-07-22 | Development Center For Biotechnology | Quinazoline compounds as kinase inhibitors |
| BR112014026952B1 (pt) * | 2012-05-03 | 2022-03-15 | Genentech, Inc | Derivados de aminopirimidina pirazol e composição que os compreende |
| WO2014081718A1 (en) * | 2012-11-20 | 2014-05-30 | Genentech, Inc. | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| JP6454651B2 (ja) * | 2013-03-15 | 2019-01-23 | プロビオドルグ エージー | 新規阻害剤 |
| MA40957A (fr) * | 2014-10-09 | 2017-09-19 | Biomarin Pharm Inc | Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies |
| CA2979302A1 (en) * | 2015-05-13 | 2016-11-17 | Selvita S.A. | Substituted quinoxaline derivatives |
| US10544095B2 (en) * | 2015-08-10 | 2020-01-28 | Pfizer Inc. | 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| US10221191B2 (en) * | 2015-12-22 | 2019-03-05 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| US10034861B2 (en) * | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
-
2017
- 2017-03-31 GB GBGB1705263.0A patent/GB201705263D0/en not_active Ceased
-
2018
- 2018-04-03 CA CA3057783A patent/CA3057783A1/en active Pending
- 2018-04-03 KR KR1020247039667A patent/KR20250002689A/ko active Pending
- 2018-04-03 IL IL297534A patent/IL297534A/en unknown
- 2018-04-03 JP JP2019553478A patent/JP7674811B2/ja active Active
- 2018-04-03 EA EA201992120A patent/EA201992120A1/ru unknown
- 2018-04-03 CN CN201880035826.8A patent/CN110719910B/zh active Active
- 2018-04-03 CA CA3221839A patent/CA3221839A1/en active Pending
- 2018-04-03 AU AU2018246382A patent/AU2018246382C1/en active Active
- 2018-04-03 KR KR1020197028930A patent/KR102737532B1/ko active Active
- 2018-04-03 IL IL269196A patent/IL269196B2/en unknown
- 2018-04-03 IL IL307911A patent/IL307911A/en unknown
- 2018-04-03 US US16/497,040 patent/US11339152B2/en active Active
- 2018-04-03 MX MX2019011544A patent/MX2019011544A/es unknown
- 2018-04-03 EP EP18718725.7A patent/EP3601269A1/en active Pending
- 2018-04-03 WO PCT/EP2018/058391 patent/WO2018178384A1/en not_active Ceased
- 2018-04-03 BR BR112019019553-0A patent/BR112019019553A2/pt active Search and Examination
- 2018-04-03 CN CN202310828597.8A patent/CN117024352A/zh active Pending
- 2018-04-03 NZ NZ792694A patent/NZ792694A/en unknown
- 2018-04-03 NZ NZ757601A patent/NZ757601A/en unknown
-
2019
- 2019-09-03 ZA ZA2019/05811A patent/ZA201905811B/en unknown
- 2019-09-26 MX MX2022007317A patent/MX2022007317A/es unknown
-
2022
- 2022-05-05 US US17/737,602 patent/US12384772B2/en active Active
- 2022-05-20 JP JP2022082769A patent/JP7589191B2/ja active Active
- 2022-10-05 AU AU2022246405A patent/AU2022246405B2/en active Active
-
2024
- 2024-07-03 JP JP2024107135A patent/JP2024153639A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12384772B2 (en) | Inhibitors | |
| EP2142514B1 (en) | Thiourea derivatives as glutaminyl cyclase inhibitors | |
| ES2468551T3 (es) | Derivados de nitrovinil-diamina como inhibidores de la glutaminil ciclasa | |
| ES2474693T3 (es) | Derivados de ciano-guanidina como inhibidores de glutaminil ciclasa | |
| KR101790806B1 (ko) | 글루타미닐 사이클라제(ｑｃ, ｅｃ 2.3.2.5)의 헤테로사이클릭 억제제 | |
| AU2009289238B2 (en) | Novel inhibitors | |
| ES2473621T3 (es) | Derivados de nitrovinil-diamina como inhibidores de glutaminil ciclasa | |
| US20260001873A1 (en) | Novel inhibitors | |
| EA043556B1 (ru) | Полициклические ингибиторы глутаминилциклазы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: VIVORYON THERAPEUTICS AG (DE) |
|
| B25D | Requested change of name of applicant approved |
Owner name: VIVORYON THERAPEUTICS N.V. (DE) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.1 NA RPI NO 2857 DE 07/10/2025 POR TER SIDO INDEVIDA. |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] |